Tumor-associated macrophages (TAMs) as new target in anticancer therapy

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 361-366

  Mantovani, Alberto ^a,b   Porta, Chiara ^a   Rubino, Luca ^a   Allavena, Paola ^a   Sica, Antonio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER; CANCER THERAPY; DRUG TARGETING; INFLAMMATION; INFLAMMATORY INFILTRATE; LEUKOCYTE ACTIVATION; REVIEW; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 33751179475     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.07.001     Document Type: Review

References (40)

1. Balkwill F., et al. Inflammation and cancer back to Virchow?. Lancet 357 (2001) 539-545
2. Mantovani A., et al. Macrophage polarization tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002) 549-555
3. Coussens L.M., et al. Inflammation and cancer. Nature 420 (2002) 860-867
4. Balkwill F., et al. Smouldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
5. Paik S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
6. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
7. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37
8. Mantovani A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004) 677-686
9. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3 (2003) 23-35
10. Biswas S.K., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107 (2006) 2112-2122
11. Pikarsky E., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
12. Greten F.R., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
13. Karin M., et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
14. Sica A., et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164 (2000) 762-767
15. Torroella-Kouri M., et al. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res. 65 (2005) 10578-10584
16. Ghosh P., et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87 (1995) 1478-1483
17. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
18. Talks K.L., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
19. Knowles H., et al. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found. Symp. 256 (2004) 189-200
20. Cramer T., et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
21. Schioppa T., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198 (2003) 1391-1402
22. Ceradini D.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
23. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
24. Guiducci C., et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65 (2005) 3437-3446
25. Sinha P., et al. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 (2005) 636-645
26. Rauh M.J., et al. The role of SHIP1 in macrophage programming and activation. Biochem. Soc. Trans. 32 (2004) 785-788
27. Bronte V., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201 (2005) 1257-1268
28. Conti I., et al. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 14 (2004) 149-154
29. Aharinejad S., et al. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res. 62 (2002) 5317-5324
30. Borrello M.G., et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U S A 102 (2005) 14825-14830
31. Phillips R.J., et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J. Biol. Chem. 280 (2005) 22473-22481
32. Carta L., et al. Engineering of macrophages to produce IFN-gamma in response to hypoxia. J. Immunol. 166 (2001) 5374-5380
33. Princen K., and Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 16 (2005) 659-677
34. Joseph I.B., et al. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst. 90 (1998) 1648-1653
35. Sessa C., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23 (2005) 1867-1874
36. Allavena P., et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin) inhibition of macrophage differentiation and cytokine production. Cancer Res. 65 (2005) 2964-2971
37. Giraudo E., et al. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114 (2004) 623-633
38. Sangaletti S., et al. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J. Exp. Med. 198 (2003) 1475-1485
39. Colombo M.P., et al. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res. 65 (2005) 9113-9116
40. Muller A.J., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005) 312-319